You are not logged in.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Khasraw, M, Ameratunga, M and Grommes, C 2014, Bevacizumab for the treatment of high-grade glioma: an update after phase III trials., Expert Opinion on Biological Therapy, vol. 14, no. 5, pp. 729-740, doi: 10.1517/14712598.2014.898060.

Attached Files
Name Description MIMEType Size Downloads

Title Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
Author(s) Khasraw, M
Ameratunga, M
Grommes, C
Journal name Expert Opinion on Biological Therapy
Volume number 14
Issue number 5
Start page 729
End page 740
Total pages 12
Publisher Informa Healthcare
Place of publication London, England
Publication date 2014-05
ISSN 1744-7682
Keyword(s) Antiangiogenic therapy
Bevacizumab
Glioblastoma
High-grade glioma
Science & Technology
Life Sciences & Biomedicine
Biotechnology & Applied Microbiology
Medicine, Research & Experimental
Research & Experimental Medicine
RECURRENT MALIGNANT GLIOMA
NEWLY-DIAGNOSED GLIOBLASTOMA
RESPONSE ASSESSMENT CRITERIA
STANDARD RADIATION-THERAPY
SINGLE-AGENT BEVACIZUMAB
PLUS IRINOTECAN
II TRIAL
MONOCLONAL-ANTIBODY
CLINICAL-TRIALS
Summary Gliomas are highly vascular and rich in VEGF, which promotes angiogenesis. Bevacizumab is a monoclonal antibody against VEGF, inhibiting angiogenesis by preventing receptor activation. Early Phase II clinical trials using bevacizumab in both newly diagnosed and recurrent high-grade gliomas (HGG) showed promising results, but these have not been confirmed in recent Phase III trials. This review is an update including recently reported Phase II and III study results.
Language eng
DOI 10.1517/14712598.2014.898060
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2014, Informa Healthcare
Persistent URL http://hdl.handle.net/10536/DRO/DU:30068176

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 17 times in TR Web of Science
Scopus Citation Count Cited 19 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 152 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 11 Dec 2014, 11:26:49 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.